TARGETING T CELL METABOLISM
IN AUTOIMMUNE DISEASES
TREATING RHEUMATOID ARTHRITIS
Rheumatech AS is a company developing drugs that can be used to treat autoimmune disease and improve life quality of patients suffering from autoimmunity. This is achieved by targeting the generation of energy in white blood cells, a therapeutic strategy on the forefront of immunological science.
The increased understanding of the pathophysiology of autoimmune disease has revealed a number of bottlenecks/checkpoints that can be targeted in order to treat or dampen disease symptoms. These include key mediators of lymphocyte adhesion and migration, destructive cytokines involved in tissue damage, and the complex of molecules critical in the presentation of self-antigen and the activation of autoaggressive T cells. In many organ-specific autoimmune diseases, the identity of the molecules recognized and attacked by T cells and B cell derived antibodies is known. Despite this, efficient treatments of various autoimmunity conditions without severe side effects have not yet been developed.
Rheumatech’s focus is on the development of a drug that targets the combustion of glucose in a way that prevents energy generation and immune cell multiplication. The idea that autoimmunity may be regulated at this level is novel and may be highly potent since it allows for the regulation of both T and B cell activity simultaneously. Moreover, the developed drug will target the underlying mechanism driving autoimmunity and hence have the potential to target multiple forms of autoimmune disease. This fact suggests that the drug that can be used to dampen the symptoms and/or treat autoimmunity regardless of disease identity.
We can't wait to hear from you
Oslo Innovation Center
Postboks 37 Vinderen